Ozempic vs Wegovy — both are semaglutide; different FDA-approved indications, doses, and pens. Factual comparison of the two brands.
Short answer: Ozempic and Wegovy are the same molecule — semaglutide — in different products. Ozempic is approved for type 2 diabetes (up to 2mg); Wegovy is approved for chronic weight management (up to 2.4mg). Different pens, different dosing schedules, different labels.
The factual comparison
| Ozempic | Wegovy |
|---|
| Active ingredient | Semaglutide | Semaglutide (identical) |
| Approved for | Type 2 diabetes (+CV/CKD benefit) | Chronic weight management |
| Max dose | 2.0 mg weekly | 2.4 mg weekly |
| Weight loss in trials | ~6–7 kg at diabetes doses | ~15% body weight |
| Nepal availability | Doctor-supervised channel | Not routinely stocked — doctor pathway |
Why two products exist
Novo Nordisk markets the same molecule under two labels because the FDA approved them for different indications at different doses — diabetes vs weight management. The drug is identical; the approval, dosing schedule, and pen differ.
In Nepal
In practice, the same supervised prescription channel handles both — a doctor assesses which product and dose fit your indication. Neither should be bought retail without a prescription.
Same molecule, different approved indications and max dose. Not interchangeable by label — a doctor decides which fits.
Wegovy's higher max dose (2.4mg) is the obesity-indicated product — trial weight loss ~15% vs Ozempic's ~6–7kg at diabetes doses.
FDA labels for Ozempic and Wegovy; STEP trial data.